Article: The Truth About Peptides
The Truth About Peptides
Peptides are everywhere right now.
BPC-157 for recovery. Tesamorelin for body composition. SS-31 and MOTS-c for mitochondrial function. CJC and ipamorelin for growth hormone signaling.
Spend enough time online and you can find a peptide for almost anything.
And that's exactly where the problem starts.
Peptides can be incredibly useful. Some are established medicines. Others are experimental compounds with interesting research behind them.
But the conversation has become too focused on one question:
What peptide should I take?
I think we're asking the wrong question.
The better question is:
What is happening inside your body that we're actually trying to change?
That's where peptide therapy gets interesting.
A peptide is a signal
The easiest way to understand peptides is to think of them as messages.
Your body is constantly communicating.
Eat food and signals change.
Exercise and signals change.
Sleep and signals change.
Hormones, metabolism, inflammation and tissue repair all depend on communication happening throughout the body.
Peptides can participate in that communication.
But different peptides send very different messages.
That's why saying "peptides work" is almost meaningless.
Which peptide?
What pathway?
For what person?
And for what reason?
Those questions matter far more than the name on the vial.
The symptom doesn't tell you the solution
Let's say someone comes into Evolve because they're exhausted.
They've been reading about SS-31 and want to try it for energy.
Maybe it makes sense.
But first I want to know why they're tired.
What if their testosterone is extremely low?
What if their thyroid is off?
What if they're insulin resistant?
What if they're sleeping terribly?
What if they're deficient in something?
What if chronic stress has been beating them up for the last three years?
And what if it's several of those things happening together?
Giving someone a peptide because they're tired is easy.
Understanding why they're tired is harder.
That's the part that matters.
This is why we test
At Evolve, we've become increasingly focused on understanding the biology before choosing the intervention.
Bloodwork gives us the first layer.
We can see what hormones are doing, how someone is handling glucose, whether inflammation is elevated, what their cardiovascular markers look like and whether there are other obvious problems hiding underneath their symptoms.
That changes the conversation immediately.
Instead of:
What's good for energy?
We can start asking:
What's limiting this person's energy?
Those sound similar.
They're completely different approaches.
And bloodwork still doesn't tell us everything.
Genetics gives us another piece of the puzzle
Two people can eat similarly, exercise similarly and live relatively similar lives while responding very differently.
Part of that difference can come from genetics.
This is why we've started integrating genetic data into how we look at optimization.
Genes can give us clues about someone's tendencies involving metabolism, inflammation, oxidative stress, hormone pathways, cardiovascular health and even how certain neurotransmitter systems function.
That doesn't mean a gene tells us what is going to happen.
It gives us context.
Bloodwork can tell us what we're seeing today.
Genetics can sometimes help us understand why that person may have ended up there — or where their biology may require more attention over time.
Now the picture becomes much more personal.
But there's another problem.
None of these systems operate alone.
The body is a network
This is systems biology.
Your sleep affects your metabolism.
Your metabolism affects your hormones.
Your hormones can affect your body composition.
Stress can affect all three.
Inflammation can influence recovery, cardiovascular health and how you feel.
Then one problem starts feeding another.
This is why I don't love looking at a single lab marker, gene or symptom and immediately attaching a treatment to it.
We're trying to understand the network.
Once you see the network, peptide therapy starts making a lot more sense.
Because now we're no longer asking:
What peptide treats fatigue?
We're asking:
Which biological system appears to be struggling, and is there a peptide that can intelligently influence it?
That's a much higher standard.
SS-31 is a good example
SS-31 is an experimental peptide being studied for its effects on mitochondrial function.
Mitochondria help our cells produce usable energy.
So naturally, SS-31 gets talked about as an "energy" or "recovery" peptide.
But imagine someone comes to us exhausted.
Their labs show poor glucose regulation. Their testosterone is low. They're sleeping five hours a night and carrying significant visceral fat.
Is their problem really that they're missing SS-31?
Probably not.
Could mitochondrial support eventually become part of the strategy?
Possibly.
But now we understand where it fits.
That's the difference between using a peptide because its description sounds like your symptom and using it as part of an actual biological strategy.
Then you have to measure what happened
This part gets overlooked constantly.
If we're trying to change someone's biology, we should have some way of determining whether we actually changed it.
Did their labs improve?
Did their body composition change?
Are they sleeping better?
Is recovery improving?
Do they feel different?
Are we seeing an unwanted effect?
If something isn't working, the answer isn't automatically to add another peptide.
Sometimes we need to change the treatment.
Sometimes we need to change the hypothesis.
This is one of the reasons I believe peptide therapy works best as part of a larger optimization program rather than as a menu of individual products.
Access is becoming the least interesting part
Anyone paying attention to this industry can see what's happening.
Peptides are becoming easier to find.
People research them online. They use AI to understand them. They listen to researchers and physicians discuss them for hours. They compare protocols with other people using them.
I don't think that's necessarily a bad thing.
An educated patient can ask much better questions.
But access to information can also create the illusion that information and understanding are the same thing.
They're not.
Knowing that a peptide affects mitochondria is information.
Knowing whether mitochondrial function is actually the limiting factor for the person sitting in front of you requires understanding.
That is where I believe this entire field is heading.
The future of peptide medicine isn't a bigger peptide menu
It is better decision-making.
We're entering a period where we can know dramatically more about a person than we could before.
Bloodwork gives us real-time biology.
Genetics adds another layer.
Body composition gives us another.
Medical history, symptoms, lifestyle and wearable data add even more.
Systems biology helps us connect those dots.
Then peptides become one of the tools we can use to influence what we find.
Sometimes the right tool will be a peptide.
Sometimes it will be hormone therapy.
Sometimes nutrition or exercise needs to change.
Sometimes someone simply needs to sleep.
And sometimes the smartest thing we can do is collect more information before doing anything.
That's the direction we're building toward at Evolve.
Not peptide therapy for the sake of peptide therapy.
Precision.
Understand the person.
Identify what appears to be limiting them.
Choose the intervention.
Measure what happens.
Then adjust.
So what's the truth about peptides?
I think peptides are going to become an increasingly important part of medicine and human optimization.
But they're tools.
And a sophisticated tool is only as useful as the thinking behind it.
The interesting question isn't whether we can give someone another peptide.
It's how much we can understand about their biology before we decide what to do.
Because getting access to peptides is becoming easy.
Knowing what your body actually needs is where the medicine begins.
Written by Michael Zaghikian
